Research programme: monoclonal antibody biosimilars - XBiotech

Drug Profile

Research programme: monoclonal antibody biosimilars - XBiotech

Alternative Names: Cancer monoclonal antibody biosimilar - XBiotech; Inflammation monoclonal antibody biosimilar - XBiotech

Latest Information Update: 27 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XBiotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Mar 2017 XBiotech has patent allowance for the administration of anti-interleukin-1 alpha antibodies to treat inflammatory skin diseases and psychiatric disorders in Australia
  • 16 Mar 2017 XBiotech has patent protection for the administration of anti-interleukin-1 alpha antibodies for the treatment of cancer in Australia, New Zealand, Philippines, Singapore, and South Africa
  • 16 Mar 2017 XBiotech has patent protection for the development of interleukin-1 alpha specific monoclonal antibodies in Australia, Chile, China, Europe, Hong Kong, Indonesia, Israel, Japan, South Korea, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top